US stock futures dip as Nvidia earnings spark little cheer
CHICAGO—Andrew Polovin, Executive Vice President and General Counsel of Tempus AI , Inc. (NASDAQ:TEM), a $7.88 billion healthcare technology company showing strong revenue growth of 30% year-over-year, recently executed a series of stock sales totaling $603,969, according to a filing with the Securities and Exchange Commission. The transactions, carried out on March 18, were part of a pre-arranged trading plan under Rule 10b5-1.
Polovin sold a total of 13,135 shares of Tempus AI’s Class A common stock. The shares were sold in multiple transactions at prices ranging from $45.78 to $47.37. Following these transactions, Polovin holds 154,171 shares in the company.
These sales were made under a trading plan adopted on September 6, 2024, allowing insiders to set up a predetermined schedule for buying or selling stock. This strategy helps mitigate concerns about insider trading by providing a systematic approach to trading company stock. For deeper insights into TEM’s valuation and 7 additional exclusive ProTips, visit InvestingPro.
In other recent news, Tempus AI reported a 35.8% increase in fourth-quarter revenue, reaching $700 million, although the earnings per share were negative at -0.18. The company has raised its 2025 revenue guidance to approximately $1.24 billion, factoring in contributions from the recent acquisition of Ambry Genetics. Stifel analysts maintained a Hold rating on Tempus AI, with a price target of $65, following the earnings report. Meanwhile, JPMorgan downgraded Tempus AI from Overweight to Neutral but raised the price target to $55, citing the company’s alignment with pre-announced earnings and a slight revenue shortfall in non-core business. Tempus AI also completed the acquisition of Deep 6 AI, enhancing its capabilities in AI-driven research platforms for healthcare. The acquisition aims to expand Tempus’s network and enhance applications that aid physicians and patients in clinical trials. These developments reflect Tempus AI’s strategic moves to strengthen its position in AI-enabled precision medicine and diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.